Related Experiment Videos

The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors

Michael Hedvat1, Dennis Huszar, Andreas Herrmann

  • 1Molecular Medicine, Beckman Research Institute, Irell & Manella Graduate School of Biological Sciences, City of Hope Cancer Center, Duarte, CA 91010, USA.

Cancer Cell
|December 8, 2009
PubMed

Insights

Persistent Stat3 activation drives cancer. Jak2 inhibitors block Stat3, suppressing tumor growth and nuclear translocation, highlighting Jaks as key targets in Stat3-dependent tumorigenesis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Signal Transduction

Background:

  • Persistent Signal transducer and activator of transcription 3 (Stat3) activation is a hallmark of many human cancers.
  • Chronic cytokine signaling is implicated in Stat3 activation, often involving Janus kinases (Jaks).

Purpose of the Study:

  • To investigate the role of Jaks in Stat3 activation and Stat3-dependent tumorigenesis in human solid tumors.
  • To evaluate the therapeutic potential of Jak2 inhibition in preclinical cancer models.

Main Methods:

  • Utilized Jak2 inhibitors (e.g., AZD1480) in human solid tumor cell lines and xenograft models.
  • Assessed Stat3 activation, nuclear translocation, and tumor growth inhibition.
  • Employed short hairpin RNA (shRNA) to target Stat3 for functional validation.

Main Results:

  • Jak2 inhibition abrogated basal and cytokine-induced Stat3 activation and nuclear translocation.
  • The Jak2 inhibitor AZD1480 suppressed the growth of human solid tumor xenografts.
  • Targeting Stat3 with shRNA confirmed its essential role downstream of Jaks in tumor growth.

Conclusions:

  • Jaks play a critical role in Stat3 activation and Stat3-dependent tumorigenesis.
  • Jak kinase activity is a key driver of tumor growth in cancers with persistent Stat3 activation.
  • Jak inhibitors represent a promising therapeutic strategy for Stat3-driven cancers.

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...